Paritaprevir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Paritaprevir (ABT-450, Veruprevir) 是一种有效的 HCV NS3/4A 蛋白酶抑制剂，对于 HCV GT 1a 和 1b 的 EC50 分别为 1 和 0.21 nM。

Paritaprevir (ABT-450, Veruprevir) is a potent HCV NS3/4A protease inhibitor with EC50 of 1 and 0.21 nM for HCV GT 1a and 1b, respectively; demonstrates in vitro antiviral activity against HCV GT1-4 and GT6 (EC50=0.09 to 19 nM), and an EC50 of 0.09 nM against GT4a; The combination of paritaprevir, ritonavir, ombitasvir (an NS5A protein inhibitor), and dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.HCV Infection Approved.

Paritaprevir has in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a.

The combination of Paritaprevir, Ritonavir, Ombitasvir (an NS5A protein inhibitor), and Dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.The acute toxicity of Paritaprevir is considered to be low. Single oral doses of ≤600 mg/kg in rats and ≤100 mg/kg in dogs produces no mortality and were well tolerated. However, since Paritaprevir is administered without ritonavir as a PK enhancer, the exposures are low, especially in male rats (rat 600 mg/kg, males: Cmax 1.82 μg/mL, AUC0-24 8.89 μg·h/mL; dog 100 mg/kg, mean: Cmax 61.3 μg/mL, AUC0-24 285 μg·h/mL).

ABT-450 | Veruprevir

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

1216941-48-8

765.8771

C40H43N7O7S

>98% (HPLC)

10 mM in DMSO

O=C([C@]([C@]1([H])/C=C\CCCCC[C@@H]2NC(C3=NC=C(C)N=C3)=O)(C1)NC([C@@](C[C@@H](OC4=C5C=CC=CC5=C(C=CC=C6)C6=N4)C7)([H])N7C2=O)=O)NS(=O)(C8CC8)=O

Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16a

(-20℃)

With Ice Pack

≥ 2 years